Methods for humanizing antibodies and humanized antibodies made thereby
View Patent ↗Disclosed herein is the use of three-dimensional structure information to guide the process of modifying antibodies with amino acids from one or more templates or surrogates such that the antigen binding properties of the parent antibody are maintained and the immunogenicity potential is reduced when administered as a therapeutic in humans.
1. A purified humanized immunoglobulin comprising a light chain variable region having an amino acid sequence selected from the group consisting of SEQ ID NO, 1 and SEQ ID NO: 5; and a heavy chain variable region having an amino acid sequence selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, and SEQ ID NO: 6.
2. The purified humanized immunoglobulin of claim 1 , wherein said light chain variable region amino acid sequence is SEQ ID NO: 1 and said heavy chain variable region amino acid sequence is SEQ ID NO: 2.
3. The purified humanized immunoglobulin of claim 1 , wherein said light chain variable region amino acid sequence is SEQ ID NO: 1 and said heavy chain variable region amino acid sequence is SEQ ID NO: 3.
4. The purified humanized immunoglobulin of claim 1 , wherein said light chain variable region amino acid sequence is SEQ ID NO: 1 and said heavy chain variable region amino acid sequence is SEQ ID NO: 4.
5. The purified humanized immunoglobulin of claim 1 , wherein said light chain variable region amino acid sequence is SEQ ID NO: 1 and said heavy chain variable region amino acid sequence is SEQ ID NO: 6.
6. The purified humanized immunoglobulin of claim 1 , wherein said light chain variable region amino acid sequence is SEQ ID NO: 5 and said heavy chain variable region amino acid sequence is SEQ ID NO, 2.
7. The purified humanized immunoglobulin of claim 1 , wherein said light chain variable region amino acid sequence is SEQ ID NO: 5 and said heavy chain variable region amino acid sequence is SEQ ID NO: 3.
8. The purified humanized immunoglobulin of claim 1 , wherein said light chain variable region amino acid sequence is SEQ ID NO: 5 and said heavy chain variable region amino acid sequence is SEQ ID NO: 4.
9. The purified humanized immunoglobulin of claim 1 , wherein said light chain variable region amino acid sequence is SEQ ID NO: 5 and said heavy chain variable region amino acid sequence is SEQ ID NO: 6.
10. The purified humanized immunoglobulin of claim 1 , wherein said humanized immunoglobulin is an antibody tetramer, Fab or (Fab) 2 .
11. A pharmaceutical composition comprising the purified humanized immunoglobulin according to claim 10 in a pharmaceutically acceptable carrier.
12. A purified humanized immunoglobulin comprising a light chain variable region having an amino acid sequence selected from the group consisting of SEQ ID NO: 13, SEQ ID NO. 15, SEQ ID NO: 17 and SEQ ID NO: 19; and a heavy chain variable region having an amino acid sequence selected from the group consisting of SEQ ID NO: 14, SEQ ID NO: 16, SEQ ID NO: 18 and SEQ ID NO: 14.
13. The purified humanized immunoglobulin of claim 12 , wherein said light chain variable region amino acid sequence is SEQ ID NO: 13 and said heavy chain variable region amino acid sequence is SEQ ID NO: 14.
14. The purified humanized immunoglobulin of claim 12 , wherein said light chain variable region amino acid sequence is SEQ ID NO: 15 and said heavy chain variable region amino acid sequence is SEQ ID NO: 16.
15. The purified humanized immunoglobulin of claim 12 , wherein said light chain variable region amino acid sequence is SEQ ID NO: 17 and said heavy chain variable region amino acid purified sequence is SEQ ID NO: 18.
16. The humanized immunoglobulin of claim 12 , wherein said light chain variable region amino acid sequence is SEQ ID NO: 19 and said heavy chain variable region amino acid sequence is SEQ ID NO: 20.
17. The purified humanized immunoglobulin of claim 12 , wherein said humanized immunoglobulin is an antibody tetramer, Fab or (Fab) 2 .
18. A pharmaceutical composition comprising purified the humanized immunoglobulin according to claim 17 in a pharmaceutically acceptable carrier.